Insider Buying Fuels Expectation of ProMIS Milestone Boost

Insider Buying Surges Amid Quiet Milestone‑Pending Deal

On February 3 2026, AB G V‑SIV IX Ltd. and its holding vehicle AB G Management Ltd. completed a sizable equity transaction involving ProMIS Neurosciences Inc. The parties acquired 700 741 shares at approximately $19.86 per share, a modest premium over the prevailing market price of $17.96. The purchase increased the group’s stake to 943 090 shares and was reported via a Form 3 filing. Although the transaction itself represents a routine equity acquisition, the timing—coincident with the company’s imminent “Milestone Event” for its PMN310 clinical program—indicates a strategic bet on forthcoming data that could materially affect the share price.

Market Dynamics and Investor Signals

The insider activity signals confidence amid recent volatility. ProMIS’s shares have fluctuated 21.92 % in the past week and 121.41 % over the month, reflecting both sector‑wide swings and company‑specific developments. The modest weekly decline notwithstanding, the buying spree by senior insiders suggests expectations that the upcoming milestone will generate a positive market reaction. For investors, this implies potential short‑term upside as new data is incorporated into price valuations, but it also highlights the need to monitor dilution risks associated with the warrants that are exercisable immediately and expire by 2031.

Warrants and Potential Dilution

Concurrently, AB G Management purchased 700 741 warrants, granting the right to acquire additional shares at the current market price within 60 days of the milestone or by February 3 2031. If the milestone is achieved, warrant exercise would increase the share base and could dilute existing shareholders. Nonetheless, the structure appears to be a long‑term commitment rather than a speculative play; the warrants provide leverage to capture upside if PMN310 progresses favorably. Investors should therefore track both the clinical data release and the timing of warrant exercises.

Broader Insider Activity

The filing is part of a broader wave of insider buying across the board. Executives such as Chief Development Officer Johanne Kaplan and Chief Scientific Officer Neil Cashman have purchased thousands of shares in recent days, bringing their holdings to 4–6 k shares each. This collective activity underscores senior management’s belief that the company’s pipeline and strategic direction are poised for growth, reinforcing the narrative that insiders are “walking the talk” with their own capital.

Implications for the Company’s Future

If the PMN310 milestone delivers robust topline data, ProMIS could experience a rally in its stock price, potentially offsetting the dilution from warrant exercise. The company’s focus on precision medicine for neurodegenerative diseases positions it favorably as demand for targeted therapeutics grows. However, the high volatility and the sizeable insider stake mean that any adverse outcome—such as a failed milestone—could amplify downward pressure. Investors should therefore monitor both the clinical data and the timing of warrant exercises, while also assessing the company’s ability to convert research milestones into commercial success.